Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis

ABSTRACT Amlitelimab is a fully human, nondepleting, anti‐OX40 ligand monoclonal antibody being investigated for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults and adolescents. Population pharmacokinetic (PopPK) and pharmacokinetic/pharmacodynamic‐Eczema Area and Severity Index...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Gilles Tiraboschi, Kim Papp, Thomas Bieber, Stephan Weidinger, Lisa Beck, Chih‐Hung Lee, John T. O'Malley, Karl Yen, Charlotte Bernigaud, David Fabre, Fabrice Hurbin
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2025-12-01
Ráidu:	CPT: Pharmacometrics & Systems Pharmacology
Fáttát:	clinical trials inflammation modeling population pharmacokinetics population pharmacokinetics‐pharmacodynamics
Liŋkkat:	https://doi.org/10.1002/psp4.70121
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!